- CA$4.04m
- CA$5.88m
- CA$1.48m
- 45
- 39
- 43
- 37
2018 November 30th | 2019 November 30th | 2020 November 30th | 2022 February 28th | 2023 February 28th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 15 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.322 | 0.094 | 0.597 | 2.38 | 1.48 |
Cost of Revenue | |||||
Gross Profit | -0.085 | -0.056 | -0.571 | -0.66 | -0.683 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Operating Interest Expense / Income | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 0.739 | 1.17 | 0.994 | 4.65 | 3.51 |
Operating Profit | -0.417 | -1.07 | -0.397 | -2.27 | -2.03 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 0.989 | -1.07 | -0.267 | -4.73 | -0.271 |
Net Income After Taxes | 0.989 | -1.07 | -0.267 | -4.73 | -0.271 |
Net Income Before Extraordinary Items | |||||
Net Income | 0.989 | -1.07 | -0.267 | -4.73 | -0.271 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 0.989 | -1.07 | -0.267 | -4.73 | -0.271 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.024 | -0.017 | -0.04 | -0.138 | -0.012 |
Dividends per Share |